Skip to main content
. 2014 Oct 11;5(23):12448–12458. doi: 10.18632/oncotarget.2558

Figure 1. Early FCH-PET/CT complete response on abiraterone treatment.

Figure 1

Baseline FCH-PET/CT shows a single left iliac nodal lesion, 5 week FCH-PET/CT resolution correlated with PSA decline and then with undetectable PSA levels (PSA < 0.03 ng/mL) after 6 months of abiraterone therapy.